e-learning
resources
ERS Research Seminars
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
When and how to identify resistance mechanisms to targeted therapies
Nicolas Girard (France)
Source:
New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Number:
6
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Nicolas Girard (France). When and how to identify resistance mechanisms to targeted therapies. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
EGFR-inhibition: resistance mechanisms and new strategies
Source: International Congress 2014 – Update on lung cancer biology for clinicians
Year: 2014
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017
Genes, mechanisms and new therapies for asthma
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Reversing glucocorticoid resistance as a new therapeutic strategy
Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD
Year: 2012
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach
Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists
Year: 2021
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs
Source: Eur Respir J 2002; 20: Suppl. 38, 613s
Year: 2002
Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use
Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia
Year: 2004
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Targeting targeted therapies: more choices and the best sequences
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018
Rational use of tuberculosis drugs to prevent the development of drug resistance
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
The resistome and other mechanisms of antibiotic resistance
Source: International Congress 2015 – Antibiotic resistance in respiratory infections
Year: 2015
Understanding the mechanisms of TKIs: the cycle of inhibition and resistance
Source: International Congress 2016 – The future of tyrosin kinase inhibitors
Year: 2016
Underlying mechanisms and pharmacological approaches for treatment of sarcopenia
Source: Virtual Congress 2021 – Sarcopenia in chronic respiratory disease: new definitions, assessment and treatment options
Year: 2021
Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept